Sulav Deo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sulav Deo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Neela Sunuwar
Emergency Medicine, Kulhudhuffushi Regional Hospital, Kulhudhuffushi, MDV
2 shared publications - Sushil Rayamajhi
Swacon International Hospital, Kathmandu
2 shared publications Anu R. Twayana
Internal Medicine, Bhaktapur Hospital, Bhaktapur, NPL
1 shared publication- Anu Radha Twayana
Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
1 shared publication - Arun Kumar Mandal
BP Koirala Institute of Health Sciences, Dharan, Nepal
1 shared publication Azwar Anjum
Emergency Medicine, Kulhudhuffushi Regional Hospital, Kulhudhuffushi, MDV
1 shared publication
Latest Publications
- Open Access
- 7 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1307-1317
Ultrasound-guided bilateral Erector Spinae Plane Block (ESPB) for postoperative analgesia in laparoscopic cholecystectomy: a randomized controlled trial
Background: Laparoscopic cholecystectomy (LC) is a commonly performed procedure with significant postoperative pain, leading to potential complications such as delayed recovery and opioid-related side effects. Regional anesthesia, particularly the Erector Spinae Plane Block (ESPB), has shown promise in improving postoperative analgesia. This study investigates the effectiveness of ultrasound-guided (USG) bilateral ESPB for pain management in LC, compared to standard multimodal analgesia. Materials and methods: This double-blind randomized controlled trial included 48 patients undergoing LC at a tertiary hospital between June 2022 and June 2023. Patients were randomly assigned to two groups: 24 received USG bilateral ESPB with 0.25% ropivacaine, and 24 received standard multimodal analgesia. Statistical analysis was conducted using t-tests, ANOVA, and chi-squared tests, with a P-value of less than 0.05 considered significant. Results: The ESPB group experienced significantly prolonged analgesia, with a mean time to rescue analgesia of 11.2 hours compared to 0.5 hours in the control group (P < 0.001). Pain scores were consistently lower in the ESPB group for the first 6 hours postoperatively. Additionally, total tramadol consumption in the ESPB group was significantly reduced (172.92 mg vs. 245.83 mg, P < 0.001). Patient satisfaction was higher in the ESPB group. Conclusion: USG bilateral ESPB significantly enhances postoperative pain management in LC, reducing both pain intensity and opioid consumption. It represents a safer alternative to opioid-based analgesia, improving recovery and patient outcomes.
- 7 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1307-1317
Open AccessUltrasound-guided bilateral Erector Spinae Plane Block (ESPB) for postoperative analgesia in laparoscopic cholecystectomy: a randomized controlled trial
Background: Laparoscopic cholecystectomy (LC) is a commonly performed procedure with significant postoperative pain, leading to potential complications such as delayed recovery and opioid-related side effects. Regional anesthesia, particularly the Erector Spinae Plane Block (ESPB), has shown promise in improving postoperative analgesia. This study investigates the effectiveness of ultrasound-guided (USG) bilateral ESPB for pain management in LC, compared to standard multimodal analgesia. Materials and methods: This double-blind randomized controlled trial included 48 patients undergoing LC at a tertiary hospital between June 2022 and June 2023. Patients were randomly assigned to two groups: 24 received USG bilateral ESPB with 0.25% ropivacaine, and 24 received standard multimodal analgesia. Statistical analysis was conducted using t-tests, ANOVA, and chi-squared tests, with a P-value of less than 0.05 considered significant. Results: The ESPB group experienced significantly prolonged analgesia, with a mean time to rescue analgesia of 11.2 hours compared to 0.5 hours in the control group (P < 0.001). Pain scores were consistently lower in the ESPB group for the first 6 hours postoperatively. Additionally, total tramadol consumption in the ESPB group was significantly reduced (172.92 mg vs. 245.83 mg, P < 0.001). Patient satisfaction was higher in the ESPB group. Conclusion: USG bilateral ESPB significantly enhances postoperative pain management in LC, reducing both pain intensity and opioid consumption. It represents a safer alternative to opioid-based analgesia, improving recovery and patient outcomes.
- Open Access
- 26 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4532-4536
Late diagnosis of dorsolumbar lipomyelomeningocele with tethered cord in a middle aged adult: A case report from Nepal
- 26 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4532-4536
Open AccessLate diagnosis of dorsolumbar lipomyelomeningocele with tethered cord in a middle aged adult: A case report from Nepal
- Open Access
- 20 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e29369
A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
The development of prostate-specific membrane antigen (PSMA) ligands labeled with radionuclides is a ground-breaking achievement in the management of prostate cancer. With the increasing use of 68Gallium-PSMA and 18F-DCFPyL (Pylarify) and their approval by the Food and Drug Administration (FDA), other PSMA agents and their unique characteristics are also being studied. Two other PSMA agents, namely 177Lutetium-PSMA (177Lu-PSMA) and 225Actinium-PSMA (225Ac-PSMA), are currently drawing the researcher’s attention mainly due to their theranostic importance. Studies focusing on the essential characteristics of these two emerging radiotracers are relatively lacking. Hence, this review article, beginning with a brief introduction, intends to provide insights on the mechanism, efficacy, adverse effects, usefulness, including theranostic implications, and limitations of these two emerging PSMA agents. The 177Lu-PSMA is commercially accessible, is well tolerated, and has been found to lower prostate-specific antigen (PSA) levels while improving patients’ quality of life. It also reduces pain and the requirement for analgesics and is safe for advanced diseases. However, despite its potential advantages, around one-third of patients do not respond satisfactorily to this costly treatment; it is still challenging to personalize this therapy and predict its outcome. Similarly, 225Ac is compatible with antibody-based targeting vectors, releasing four extremely hazardous high-energy emissions with a longer half-life of 10 days. It has made 225Ac-PSMA therapy useful for tumors resistant to standard treatments, with a better response than 177Lu-PSMA. Dosimetry studies show a good biochemical response without toxicity in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). However, it can potentially cause significant damage to healthy tissues if not retained at the tumor site. Encapsulating radionuclides in a nano-carrier, hastening the absorption by tumor cells, and local delivery might all help reduce the harmful consequences. Both have advantages and disadvantages. The choice of PSMA agents may rely on desired qualities, cost, and convenience, among other factors. Further research is warranted in order to better understand their ideal use in clinical settings.
- 20 September 2022
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e29369
Open AccessA Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
The development of prostate-specific membrane antigen (PSMA) ligands labeled with radionuclides is a ground-breaking achievement in the management of prostate cancer. With the increasing use of 68Gallium-PSMA and 18F-DCFPyL (Pylarify) and their approval by the Food and Drug Administration (FDA), other PSMA agents and their unique characteristics are also being studied. Two other PSMA agents, namely 177Lutetium-PSMA (177Lu-PSMA) and 225Actinium-PSMA (225Ac-PSMA), are currently drawing the researcher’s attention mainly due to their theranostic importance. Studies focusing on the essential characteristics of these two emerging radiotracers are relatively lacking. Hence, this review article, beginning with a brief introduction, intends to provide insights on the mechanism, efficacy, adverse effects, usefulness, including theranostic implications, and limitations of these two emerging PSMA agents. The 177Lu-PSMA is commercially accessible, is well tolerated, and has been found to lower prostate-specific antigen (PSA) levels while improving patients’ quality of life. It also reduces pain and the requirement for analgesics and is safe for advanced diseases. However, despite its potential advantages, around one-third of patients do not respond satisfactorily to this costly treatment; it is still challenging to personalize this therapy and predict its outcome. Similarly, 225Ac is compatible with antibody-based targeting vectors, releasing four extremely hazardous high-energy emissions with a longer half-life of 10 days. It has made 225Ac-PSMA therapy useful for tumors resistant to standard treatments, with a better response than 177Lu-PSMA. Dosimetry studies show a good biochemical response without toxicity in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). However, it can potentially cause significant damage to healthy tissues if not retained at the tumor site. Encapsulating radionuclides in a nano-carrier, hastening the absorption by tumor cells, and local delivery might all help reduce the harmful consequences. Both have advantages and disadvantages. The choice of PSMA agents may rely on desired qualities, cost, and convenience, among other factors. Further research is warranted in order to better understand their ideal use in clinical settings.
- Open Access
- 9 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27807
Salt-Wasting Form of Congenital Adrenal Hyperplasia: A Case Report
Congenital adrenal hyperplasia (CAH) is a set of autosomal recessive disorders characterized by enzyme abnormalities in the adrenal steroidogenesis pathway, which cause impaired cortisol biosynthesis. Glucocorticoid, mineralocorticoid, and sex steroid production can all be altered in individuals, necessitating hormone replacement therapy. The symptoms might range from prenatal salt loss and abnormal genitalia to adult hirsutism and irregular menses. We present the case of a girl who presented with a seizure initially at the age of three months. Laboratory results revealed hypoglycemia, hyponatremia, and hyperkalemia with increased renin activity, increased adrenocorticotropic hormone (ACTH), low aldosterone, low cortisol, high dehydroepiandrosterone sulfate (DHEAS), and high 17 hydroxyprogesterone levels. Imaging findings were normal. The patient was managed with hydrocortisone and fludrocortisone. She is currently on regular follow-up and is doing well with dexamethasone therapy.
- 9 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e27807
Open AccessSalt-Wasting Form of Congenital Adrenal Hyperplasia: A Case Report
Congenital adrenal hyperplasia (CAH) is a set of autosomal recessive disorders characterized by enzyme abnormalities in the adrenal steroidogenesis pathway, which cause impaired cortisol biosynthesis. Glucocorticoid, mineralocorticoid, and sex steroid production can all be altered in individuals, necessitating hormone replacement therapy. The symptoms might range from prenatal salt loss and abnormal genitalia to adult hirsutism and irregular menses. We present the case of a girl who presented with a seizure initially at the age of three months. Laboratory results revealed hypoglycemia, hyponatremia, and hyperkalemia with increased renin activity, increased adrenocorticotropic hormone (ACTH), low aldosterone, low cortisol, high dehydroepiandrosterone sulfate (DHEAS), and high 17 hydroxyprogesterone levels. Imaging findings were normal. The patient was managed with hydrocortisone and fludrocortisone. She is currently on regular follow-up and is doing well with dexamethasone therapy.
- Open Access
- 1 August 2022
- Published by Journal of Nepal Medical Association (JNMA) in Journal of Nepal Medical Association
- Vol. 60 (252) , 743-746
Congenital Upper Limb Deficiency with Oligodactyly: A Case Report
Congenital upper limb deficiency care and management have undergone drastic changes over the past 50 years. Given the low incidence of this defect nationwide, this case report adds to the existing database to analyze the etiological investigations, descriptive epidemiology, and trend detection. We present a case of a 2-month-old male child with congenital upper limb deficiency and explore the possible etiologies and difficulties during early diagnosis of such rare disorders in a low and middle-income countrries and present implications at the primary health care level to improve the prognosis. Poor nutrition during pregnancy due to an unplanned pregnancy is a possible cause. The prognosis is unfavourable due to sociocultural barriers. To address these limitations, it is pertinent to address disability-adequate knowledge among communities, promote early diagnosis, and timely rehabilitation using a multidisciplinary approach. Further, we provide a framework to optimize care.
- 1 August 2022
- Published by Journal of Nepal Medical Association (JNMA) in Journal of Nepal Medical Association
- Vol. 60 (252) , 743-746
Open AccessCongenital Upper Limb Deficiency with Oligodactyly: A Case Report
Congenital upper limb deficiency care and management have undergone drastic changes over the past 50 years. Given the low incidence of this defect nationwide, this case report adds to the existing database to analyze the etiological investigations, descriptive epidemiology, and trend detection. We present a case of a 2-month-old male child with congenital upper limb deficiency and explore the possible etiologies and difficulties during early diagnosis of such rare disorders in a low and middle-income countrries and present implications at the primary health care level to improve the prognosis. Poor nutrition during pregnancy due to an unplanned pregnancy is a possible cause. The prognosis is unfavourable due to sociocultural barriers. To address these limitations, it is pertinent to address disability-adequate knowledge among communities, promote early diagnosis, and timely rehabilitation using a multidisciplinary approach. Further, we provide a framework to optimize care.
- 1 September 2021
- Published by Elsevier in Public Health
- Vol. 198, 89-95
Impact of maternal decision-making autonomy and self-reliance in accessing health care on childhood diarrhea and acute respiratory tract infections in Nepal
- 1 September 2021
- Published by Elsevier in Public Health
- Vol. 198, 89-95
Impact of maternal decision-making autonomy and self-reliance in accessing health care on childhood diarrhea and acute respiratory tract infections in Nepal
- Open Access
- 18 August 2021
- Published by School of Health and Allied Sciences Faculty of Heath Sciences in Journal of Health and Allied Sciences
- Vol. 11 (1) , 14-23
Japanese Encephalitis Mass Vaccination Coverage Survey in Five Districts of Nepal
Introduction: The World Health Organization recommends mass vaccination campaigns in children under 15 years before introducing the Japanese Encephalitis (JE) vaccine into the routine immunization program as the most effective immunization strategy in JE disease-endemic countries. The study was conducted to assess the JE vaccine coverage during the recent mass vaccination campaign in five districts of Nepal in 2016. Methods: A stratified three-stage cluster design was used for this cross-sectional sample survey. The JE mass vaccination campaign of 2016 targeted children aged between 1-14 years, and the interview was conducted among systematically sampled households’ mothers and guardians of children aged between 2-15 years in 2017. Results: The coverage of the JE mass vaccination campaign in the year 2016 was 96.9%; the males had slightly higher coverage (97.4%) than females (96.6%). The vaccine utilization increased with an increase in age, 94.0%, 98.1%, and 99.1% coverage among children aged 2-5 years, 6-10 years, and 10-15 years, respectively. The school enrolled children were four-times (OR: 4.016, CI: 2.595–6.216) likely to be vaccinated than out-of-school children and association was statistically significant. Among 86 children who were not vaccinated, 45.3% were ill during the campaign. Besides, 6.6% of out of school children also didn’t get the vaccination. Only three in ten (30.4%) respondents knew that the JE vaccine was given to protect against JE disease or brain fever. More than one-third (36.3%) of respondents reported that the recommendation from the health workers was main reason for vaccinating their children. Only 1.1% of vaccinated children had minor issues following vaccination. Conclusion: Despite low awareness about the specific protection of the JE vaccine, the vaccination coverage was high during the JE mass vaccination campaign. Increasing awareness about the particular vaccine and including activities to vaccinate out-of-school children could help achieve universal coverage in future mass vaccination campaigns
- 18 August 2021
- Published by School of Health and Allied Sciences Faculty of Heath Sciences in Journal of Health and Allied Sciences
- Vol. 11 (1) , 14-23
Open AccessJapanese Encephalitis Mass Vaccination Coverage Survey in Five Districts of Nepal
Introduction: The World Health Organization recommends mass vaccination campaigns in children under 15 years before introducing the Japanese Encephalitis (JE) vaccine into the routine immunization program as the most effective immunization strategy in JE disease-endemic countries. The study was conducted to assess the JE vaccine coverage during the recent mass vaccination campaign in five districts of Nepal in 2016. Methods: A stratified three-stage cluster design was used for this cross-sectional sample survey. The JE mass vaccination campaign of 2016 targeted children aged between 1-14 years, and the interview was conducted among systematically sampled households’ mothers and guardians of children aged between 2-15 years in 2017. Results: The coverage of the JE mass vaccination campaign in the year 2016 was 96.9%; the males had slightly higher coverage (97.4%) than females (96.6%). The vaccine utilization increased with an increase in age, 94.0%, 98.1%, and 99.1% coverage among children aged 2-5 years, 6-10 years, and 10-15 years, respectively. The school enrolled children were four-times (OR: 4.016, CI: 2.595–6.216) likely to be vaccinated than out-of-school children and association was statistically significant. Among 86 children who were not vaccinated, 45.3% were ill during the campaign. Besides, 6.6% of out of school children also didn’t get the vaccination. Only three in ten (30.4%) respondents knew that the JE vaccine was given to protect against JE disease or brain fever. More than one-third (36.3%) of respondents reported that the recommendation from the health workers was main reason for vaccinating their children. Only 1.1% of vaccinated children had minor issues following vaccination. Conclusion: Despite low awareness about the specific protection of the JE vaccine, the vaccination coverage was high during the JE mass vaccination campaign. Increasing awareness about the particular vaccine and including activities to vaccinate out-of-school children could help achieve universal coverage in future mass vaccination campaigns